-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Avid Bioservices Earnings Perspective: Return On Invested Capital
Avid Bioservices Earnings Perspective: Return On Invested Capital
According to Benzinga Pro data Avid Bioservices (NASDAQ:CDMO) posted a 98.65% decrease in earnings from Q4. Sales, however, increased by 17.5% over the previous quarter to $36.69 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Avid Bioservices is not utilizing their capital as effectively as possible. Avid Bioservices reached earnings of $115.60 million and sales of $31.23 million in Q4.
What Is Return On Invested Capital?
Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Avid Bioservices posted an ROIC of 0.86%.
It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.
ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Avid Bioservices is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For Avid Bioservices, the positive return on invested capital ratio of 0.86% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
Upcoming Earnings Estimate
Avid Bioservices reported Q1 earnings per share at $0.05/share, which beat analyst predictions of $0.04/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
According to Benzinga Pro data Avid Bioservices (NASDAQ:CDMO) posted a 98.65% decrease in earnings from Q4. Sales, however, increased by 17.5% over the previous quarter to $36.69 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Avid Bioservices is not utilizing their capital as effectively as possible. Avid Bioservices reached earnings of $115.60 million and sales of $31.23 million in Q4.
根據Benzinga Pro的數據狂熱的生物服務納斯達克(Sequoia Capital:CDMO)公佈第四季度收益同比下降98.65%。然而,銷售額比上一季度增長了17.5%,達到3669萬美元。儘管本季度銷售額有所增長,但收益的下降可能表明Avid Bioservices沒有儘可能有效地利用資本。Avid生物服務公司第四季度的收入為1.156億美元,銷售額為3123萬美元。
What Is Return On Invested Capital?
什麼是投資資本回報?
Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Avid Bioservices posted an ROIC of 0.86%.
沒有背景的收益數據不清楚,很難作為交易決定的依據。投資資本回報率(ROIC)通過衡量企業相對於投資資本的年度税前利潤,幫助過濾噪聲中的信號。一般來説,較高的ROIC意味着公司的成功增長,也是未來每股收益較高的跡象。第一季度,艾維德生物服務公司的ROIC為0.86%。
It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.
重要的是要記住,ROIC評估的是過去的業績,而不是用作預測工具。這是衡量一家公司近期表現的一個很好的指標,但沒有考慮到可能在不久的將來影響收益和銷售的因素。
ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Avid Bioservices is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
ROIC是比較類似公司資本配置有效性的有力指標。相對較高的ROIC表明,Avid生物服務公司的運營效率可能比其行業內的其他公司更高。如果公司以目前的投資資本水平產生高利潤,其中一些資金可以再投資於更多資本,這通常會帶來更高的回報,並最終實現每股收益(EPS)的增長。
For Avid Bioservices, the positive return on invested capital ratio of 0.86% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
對於艾維德生物服務公司,0.86%的正投資資本回報率表明管理層正在有效地配置資本。有效的資本配置是一個積極的指標,表明一家公司將獲得更持久的成功和有利的長期回報。
Upcoming Earnings Estimate
即將到來的收益預期
Avid Bioservices reported Q1 earnings per share at $0.05/share, which beat analyst predictions of $0.04/share.
Avid Bioservices公佈第一季度每股收益為0.05美元,超過分析師預測的0.04美元。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動內容引擎生成,並由編輯審閲。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧